{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:26:04Z","timestamp":1758817564666,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immunocompromised patients are at high risk of complicated severe acute respiratory coronavirus\u00a02 infection. The aim of this retrospective study was to describe the characteristics and outcomes of heart transplantation (HTx) recipients with coronavirus disease 2019 (COVID-19) in the Netherlands.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>HTx patients from one of the three HTx centres in the Netherlands with COVID-19 (proven by positive reverse-transcription polymerase chain reaction or serology test result) between February 2020 and June 2021 were included. The primary endpoint was all-cause mortality and the secondary endpoint was disease severity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>COVID-19 was diagnosed in 54\/665 HTx patients (8%), with a\u00a0mean (\u00b1\u202fstandard deviation (SD)) time after HTx of 11\u202f\u00b1\u20098\u00a0years. Mean (\u00b1\u202fSD) age was 53\u202f\u00b1\u200914\u00a0years and 39% were female. Immunosuppressive therapy dosage was reduced in 37% patients (20\/54). Hospitalisation was required in 39% patients (21\/54), and 13% patients (7\/54) had severe COVID-19 (leading to intensive care unit (ICU) admission or death). In-hospital mortality was 14% (3\/21), and all-cause mortality was 6%. Compared with patients with moderate COVID-19 (hospitalised without ICU indication), severe COVID-19 patients tended to be transplanted earlier and had a\u00a0significantly higher mean (\u00b1\u202fSD) body mass index (26\u202f\u00b1\u20093 vs 30\u202f\u00b1\u20093\u202fkg\/m<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic>\u202f=\u20090.01). Myocardial infarction, cellular rejection and pulmonary embolism were observed once in three different HTx patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>HTx patients were at increased risk of complicated COVID-19 with frequent hospitalisation, but the all-cause mortality was substantially lower than previously described (7\u201333%).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12471-022-01720-9","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T14:03:07Z","timestamp":1662645787000},"page":"519-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Characteristics and outcomes of COVID-19 in heart transplantation recipients in the Netherlands"],"prefix":"10.1007","volume":"30","author":[{"given":"S. A.","family":"Muller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. C.","family":"Manintveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. K.","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Damman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. G.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. W.","family":"van Laake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-518X","authenticated-orcid":false,"given":"M. I. F. J.","family":"Oerlemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"1720_CR1","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu. Epidemiologische situatie van SARS-CoV\u20112 in Nederland.. www.rivm.nl\/sites\/default\/files\/2022-05\/COVID-19_WebSite_rapport_wekelijks_20220510_1259_final.pdf. Accessed 11 May 2022."},{"key":"1720_CR2","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/ajt.16369","volume":"21","author":"E Coll","year":"2021","unstructured":"Coll\u00a0E, Fern\u00e1ndez-Ruiz\u00a0M, S\u00e1nchez-\u00c1lvarez\u00a0JE, et al. COVID-19 in transplant recipients: the Spanish experience. Am J Transplant. 2021;21:1825\u201337.","journal-title":"Am J Transplant"},{"key":"1720_CR3","first-page":"1","volume":"27","author":"RB Azevedo","year":"2020","unstructured":"Azevedo\u00a0RB, Botelho\u00a0BP, de Hollanda\u00a0JVG, et al. Covid-19 and the cardiovascular system: a\u00a0comprehensive review. J\u00a0Hum Hypertens. 2020;27:1\u20138.","journal-title":"J Hum Hypertens"},{"key":"1720_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/vaccines9070708","volume":"9","author":"M Narasimhan","year":"2021","unstructured":"Narasimhan\u00a0M, Mahimainathan\u00a0L, Clark\u00a0AE, et al. Serological response in lung transplant recipients after two doses of SARS-CoV\u20112 mRNA vaccines. Vaccines. 2021;9:708.","journal-title":"Vaccines"},{"key":"1720_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.healun.2021.04.003","volume":"40","author":"Y Peled","year":"2021","unstructured":"Peled\u00a0Y, Ram\u00a0E, Lavee\u00a0J, et\u00a0al. BNT162b vaccination in heart transplant recipients: clinical experience and antibody response. J\u00a0Heart Lung Transplant. 2021;40:759\u201362.","journal-title":"J Heart Lung Transplant"},{"key":"1720_CR6","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/tri.14029","volume":"34","author":"M Gianella","year":"2021","unstructured":"Gianella\u00a0M, Pierrotti\u00a0LC, Helanter\u00e4\u00a0I, Manuel\u00a0O. SARS-CoV\u20112 vaccination in solid-organ transplant recipients: what the clinician needs to know. Transpl Int. 2021;34:1776\u201388.","journal-title":"Transpl Int"},{"key":"1720_CR7","first-page":"1165","volume":"2020","author":"F Latif","year":"2019","unstructured":"Latif\u00a0F, Farr\u00a0MA, Clerkin\u00a0KJ, et\u00a0al. Characteristics and outcomes of recipients of heart transplant with coronavirus disease. JAMA Cardiol. 2019;2020:1165\u20139.","journal-title":"JAMA Cardiol"},{"key":"1720_CR8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.healun.2021.05.006","volume":"40","author":"MV Genuardi","year":"2021","unstructured":"Genuardi\u00a0MV, Moss\u00a0N, Najjar\u00a0SS, et\u00a0al. Coronavirus disease 2019 in heart transplant recipients: risk factors, immunosuppression, and outcomes. J\u00a0Heart Lung Transplant. 2021;40:926\u201335.","journal-title":"J Heart Lung Transplant"},{"key":"1720_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jchf.2020.10.009","volume":"9","author":"T Bottio","year":"2021","unstructured":"Bottio\u00a0T, Bagozzi\u00a0L, Fiocco\u00a0A, et al. COVID-19 in heart transplant recipients: a multicenter analysis of the northern Italian outbreak. JACC Heart Fail. 2021;9:52\u201361.","journal-title":"JACC Heart Fail"},{"key":"1720_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/TP.0000000000003770","volume":"106","author":"FG Marcondes-Braga","year":"2021","unstructured":"Marcondes-Braga\u00a0FG, Murad\u00a0CM, Belfort\u00a0DSP, et al. Characteristics and outcomes of heart transplant recipients with coronavirus-19 disease in a high-volume transplant center. Transplantation. 2021;106:641\u20137.","journal-title":"Transplantation"},{"key":"1720_CR11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1097\/TP.0000000000003670","volume":"105","author":"YB Hadi","year":"2021","unstructured":"Hadi\u00a0YB, Naqvi\u00a0SFZ, Kupec\u00a0JT, Sofka\u00a0S, Sarwari\u00a0A. Outcomes of COVID-19 in solid organ transplant recipients: a propensity-matched analysis of a\u00a0large research network. Transplantation. 2021;105:1365\u201371.","journal-title":"Transplantation"},{"key":"1720_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/TP.0000000000003436","volume":"105","author":"M Felldin","year":"2021","unstructured":"Felldin\u00a0M, S\u00f8fteland\u00a0JM, Magnusson\u00a0J, et al. Initial report from a\u00a0Swedish high-volume transplant center after the first wave of the COVID-19 pandemic. Transplantation. 2021;105:108\u201314.","journal-title":"Transplantation"},{"key":"1720_CR13","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1097\/TP.0000000000003873","volume":"105","author":"E Coll","year":"2021","unstructured":"Coll\u00a0E, Fern\u00e1ndez-Ruiz\u00a0M, Padilla\u00a0M, et al. COVID-19 in solid organ transplant recipients in Spain throughout 2020: catching the wave? Transplantation. 2021;105:2146\u201355.","journal-title":"Transplantation"},{"key":"1720_CR14","doi-asserted-by":"publisher","first-page":"e4090","DOI":"10.1093\/cid\/ciaa1097","volume":"73","author":"OS Kates","year":"2021","unstructured":"Kates\u00a0OS, Haydel\u00a0BM, Florman\u00a0SS, et\u00a0al. Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study. Clin Infect Dis. 2021;73:e4090\u20139.","journal-title":"Clin Infect Dis"},{"key":"1720_CR15","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s00392-020-01722-w","volume":"109","author":"R Rivinius","year":"2020","unstructured":"Rivinius\u00a0R, Kaya\u00a0Z, Schramm\u00a0R, et al. COVID-19 among heart transplant recipients in Germany: a\u00a0multicenter survey. Clin Res Cardiol. 2020;109:1531\u20139.","journal-title":"Clin Res Cardiol"},{"key":"1720_CR16","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams\u00a0B, Mancia\u00a0G, Spiering\u00a0W, et\u00a0al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart\u00a0J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"1720_CR17","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","year":"2011","unstructured":"The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart\u00a0J. 2011;32:1769\u2013818.","journal-title":"Eur Heart J"},{"key":"1720_CR18","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryd\u00e9n","year":"2013","unstructured":"Ryd\u00e9n\u00a0L, Grant\u00a0PJ, Anker\u00a0SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart\u00a0J. 2013;34:3035\u201387.","journal-title":"Eur Heart J"},{"key":"1720_CR19","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jinf.2020.08.029","volume":"81","author":"E Garrigues","year":"2020","unstructured":"Garrigues\u00a0E, Janvier\u00a0P, Kherabi\u00a0Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J\u00a0Infect. 2020;81:e4\u20136.","journal-title":"J Infect"},{"key":"1720_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/jmv.26368","volume":"93","author":"SJ Halpin","year":"2021","unstructured":"Halpin\u00a0SJ, McIvor\u00a0C, Whyatt\u00a0G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J\u00a0Med Virol. 2021;93:1013\u201322.","journal-title":"J Med Virol"},{"key":"1720_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/all.14657","volume":"76","author":"YD Gao","year":"2021","unstructured":"Gao\u00a0YD, Ding\u00a0M, Dong\u00a0X, et al. Risk factors for severe and critically ill COVID-19\u00a0patients: a review. Allergy. 2021;76:428\u201355.","journal-title":"Allergy"},{"key":"1720_CR22","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jchf.2015.06.012","volume":"3","author":"S Shore","year":"2015","unstructured":"Shore\u00a0S, Grau-Sepulveda\u00a0MV, Bhatt\u00a0DL, et al. Characteristics, treatments, and outcomes of hospitalized heart failure patients stratified by etiologies of cardiomyopathy. JACC Heart Fail. 2015;3:906\u201316.","journal-title":"JACC Heart Fail"},{"key":"1720_CR23","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3390\/v13091879","volume":"13","author":"D D\u0119borska-Materkowska","year":"2021","unstructured":"D\u0119borska-Materkowska\u00a0D, Kami\u0144ska\u00a0D. The immunology of SARS-CoV\u20112 infection and vaccines in solid organ transplant recipients. Viruses. 2021;13:1879.","journal-title":"Viruses"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-022-01720-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-022-01720-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-022-01720-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T07:40:54Z","timestamp":1666856454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-022-01720-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1720"],"URL":"https:\/\/doi.org\/10.1007\/s12471-022-01720-9","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"type":"print","value":"1568-5888"},{"type":"electronic","value":"1876-6250"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"2 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.W.\u00a0van Laake has received consultancy fees from Abbott, Medtronic, Vifor and Novartis, which were paid to the University Medical Centre Utrecht. M.I.F.J.\u00a0Oerlemans has received consultancy fees from Abbott, Medtronic, Vifor, Novartis, Pfizer and Alnylam which were paid to the University Medical Centre Utrecht. S.A.\u00a0Muller, O.C.\u00a0Manintveld, M.K.\u00a0Szymanski, K.\u00a0Damman, M.G.\u00a0van der Meer and K.\u00a0Caliskan declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}